SCHEDULE 13G - Helix Acquisition Corp. II (0001869105) (Subject)
424B3 - Helix Acquisition Corp. II (0001869105) (Filer)
425 - Helix Acquisition Corp. II (0001869105) (Subject)
425 - Helix Acquisition Corp. II (0001869105) (Subject)
8-K - Helix Acquisition Corp. II (0001869105) (Filer)
S-4/A - Helix Acquisition Corp. II (0001869105) (Filer)
S-4 - Helix Acquisition Corp. II (0001869105) (Filer)
10-Q - Helix Acquisition Corp. II (0001869105) (Filer)
SCHEDULE 13G - Helix Acquisition Corp. II (0001869105) (Subject)
10-K - Helix Acquisition Corp. II (0001869105) (Filer)
3 - Helix Acquisition Corp. II (0001869105) (Issuer)
4 - Helix Acquisition Corp. II (0001869105) (Issuer)
4 - Helix Acquisition Corp. II (0001869105) (Issuer)
Extraordinary General Meeting of Helix Shareholders Scheduled for August 4, 2025 SOUTH SAN FRANCISCO & BOSTON, July 11, 2025 (GLOBE NEWSWIRE) -- Helix Acquisition Corp. II ("Helix") (NASDAQ:HLXB), a special purpose acquisition company ("SPAC") sponsored by Cormorant Asset Management, and TheRas, Inc. (d/b/a BridgeBio Oncology Therapeutics) ("BBOT"), a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies, today announced that the registration statement on Form S-4 (File No. 333-288222) (as amended, the "Registration Statement"), filed by Helix and BBOT, relating to the previously-announced b
Total proceeds, assuming no redemptions, are expected to be $450 million, combining funds held in the Helix Acquisition Corp. II trust account and a private investment in public equity (PIPE) financing Leading institutional investors commit approximately $260 million through a PIPE led by Cormorant Asset Management Business combination is expected to be completed in the third quarter of 2025 The combined entity will be named BridgeBio Oncology Therapeutics (BBOT) and will be advancing a next-generation pipeline of therapies for patients with RAS and PI3Kα malignancies TheRas, Inc. d/b/a BridgeBio Oncology Therapeutics ("BBOT"), a clinical-stage biopharmaceutical company advanci
SC 13G - Helix Acquisition Corp. II (0001869105) (Subject)
SC 13G - Helix Acquisition Corp. II (0001869105) (Subject)
SC 13G - Helix Acquisition Corp. II (0001869105) (Subject)
SC 13D - Helix Acquisition Corp. II (0001869105) (Subject)